内斗不止，分红530亿：科兴生物遭纳斯达克驱逐退市

Core Viewpoint - Sinovac Biotech, once a leading player in the vaccine industry, is facing a severe delisting crisis due to a prolonged internal power struggle rather than market competition or business decline [1] Group 1: Company Background - Sinovac Biotech was founded in 2001 by Yin Weidong and Pan Aihua, combining technical expertise and capital investment [2] - The company expanded its product line from hepatitis A vaccine to various vaccines, including those for influenza and SARS [2][3] - Sinovac successfully went public on NASDAQ, but internal conflicts began to emerge as the company grew [3] Group 2: Internal Conflicts - Fundamental disagreements arose between the founders regarding the ownership and control of the company, leading to factionalism among shareholders [3] - The conflict escalated in 2018, resulting in physical altercations at the company’s facilities and significant financial losses, including the destruction of 6 million vaccine doses [3] - NASDAQ suspended trading of Sinovac shares in 2019 due to the company's failure to provide required information, leading to a stagnant stock price of $6.47 and a market cap of approximately 28 billion RMB [3] Group 3: Financial Performance and Dividends - The COVID-19 pandemic provided a temporary revival for Sinovac, with the company earning a net profit of $8.46 billion (approximately 600 billion RMB) in 2021 from its vaccine [4] - Despite the financial success, internal disputes meant that not all founders benefited equally, with Pan Aihua receiving no dividends and facing legal issues [4] - A controversial "liquidation-style dividend" proposal was introduced, offering up to $124 per share, totaling around 74.4 billion USD (approximately 530 billion RMB), which was overwhelmingly supported by shareholders [6] Group 4: Current Situation and Future Outlook - The company is currently in a precarious position, having failed to publish its annual report on time, leading to NASDAQ's decision to delist it on November 21 [6][7] - Sinovac has appealed the delisting decision, but the situation appears more dire than previous instances [6][7] - The internal power struggle has left the company in a state of decline, with no clear winners among the founders or shareholders [7]